1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Hubei Goto Biopharm Co.,Ltd.

Hubei Goto Biopharm Co.,Ltd.

300966.SZ
Hubei Goto Biopharm Co.,Ltd.CN flagShenzhen Stock Exchange
29.66
CNY
-0.37
- -
3.42BMarket Cap
Hubei Goto Biopharm Co.,Ltd.
300966.SZ
(Shenzhen Stock Exchange)

Recent

price

29.66

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
7.25
5.2
5.41
5.45
5.59
5.26
4.92
4.67
5.29
5.59
Revenue per Share
1.03
0.84
0.85
0.62
0.74
0.35
0.2
-0.24
-0.64
-0.31
Basic EPS, GAAP
-0.91
-0.73
-0.29
-0.06
-0.31
-3.76
-2.97
-2.89
-1.09
-2.31
Free Cash Flow per Basic Share
0.07
0.05
0.11
0.11
0.07
0.23
0.05
0.22
0.26
0.25
Dividend per Share
2.96
1.93
2.7
3.3
3.67
3.59
3.79
3.53
2.9
3.65
Book Value per Share
6.23
4.69
5.35
6.04
7.58
8.17
8.46
8.39
7.46
8.76
Tangible Book Value per Share
46
84
86
86
106
115
115
115
115
108
Basic Weighted Avg Shares
334
437
465
468
591
605
566
537
606
605
Sales/Revenue/Turnover
18.58
19.82
19.98
14.08
12.26
8.75
7.37
-0.39
-5.54
2.1
Operating Margin (%)
10
15
17
21
23
27
28
43
115
- -
Depreciation Expense
47
71
73
53
78
40
23
-28
-73
-34
Net Income, GAAP
14.74
12.08
11.85
11.7
9.35
- -
- -
- -
- -
- -
Effective Tax Rate (%)
14.22
16.16
15.7
11.38
13.26
6.65
4.06
-5.14
-12.1
-5.56
Profit Margin (%)
123
239
291
332
525
638
183
-38
-52
33
Working Capital
- -
- -
- -
1
7
441
653
813
974
965
LT Debt
300
408
481
540
828
981
1,024
1,015
909
997
Total Equity
- -
18.95
15.5
9.29
7.93
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
42.13
30.07
16.14
16.64
- -
- -
- -
- -
- -
Return on Capital (%)
- -
47.31
37.04
20.68
23.32
10.04
5.42
-6.56
-19.86
-8.17
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
319
320
261
LT Borrowings
813
920
965
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
115
115
115
Market Capitalization
1,907
1,746
1,983

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
770
872
855
Cash, Cash Equivalents & STI
141
157
134
Accounts Receivable, Net
189
212
239
Inventories
385
433
440
Total Current Liabilities
808
827
822
Payables & Accruals
- -
- -
- -
ST Debt
319
320
261
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
12.99%
-10.38%
Free Cash Flow
- -
334.75%
-62.29%
Net Income, GAAP
- -
-19.7%
165.88%
Sales/Revenue/Turnover
- -
5.99%
12.97%
Total Cash Common Dividend
- -
99.65%
16.11%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
122
112
132
171
537
2025
139
163
151
- -
606
2026
162
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
- -
- -
- -
-0.24
2025
0.01
- -
- -
- -
-0.64
2026
0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
- -
- -
- -
0.22
2025
0.03
- -
- -
- -
0.26
2026
0.05
- -
- -
- -
- -
Similar Companies
Gain Therapeutics, Inc. (GANX)
Capricor Therapeutics, Inc. (CAPR)
Albert Labs International Corp. (ABRT.CN)
Akebia Therapeutics, Inc. (AKBA)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Sunny Pharmtech Inc. (6676.TWO)
Business
Hubei Goto Biopharm Co.,Ltd. specializes in the research, development, production, and global distribution of steroidal pharmaceutical raw materials and intermediates. The company provides essential starting compounds, including 9a-hydroxy-4-androstenedione (9a-OHAD), bisnoralcohol (BA), 1,4-androstadienedione (ADD), and 4-androstenedione (4-AD), derived from plant sterols through advanced bioconversion. Its offerings further extend to various intermediates, such as those for sex hormones, progesterone, and corticosteroids, alongside other active pharmaceutical ingredients. Established in 2006, the high-tech enterprise maintains its primary operations in Yicheng, China, and was listed on the GEM of the Shenzhen Stock Exchange in April 2021. The firm is recognized as a significant supplier in the steroid drug intermediate sector, emphasizing its comprehensive product chain and robust R&D capabilities in molecular biology, enzyme engineering, and chemical synthesis.